4.18
0.00 (0.00%)
0.00 (0.00%)
Upgrade to Real-Time
Afterhours (Closed)
Best deals to access real time data! |
|
Big Cap Pro
Monthly Subscription
for only
|
|
Real-Time Alerts for Volume Breakouts, Highs and Lows for NYSE, NASDAQ, Amex, OTC Markets and OTCBB
Monthly Subscription
for only
|
|
Level 1 Starter
Monthly Subscription
for only
|
|
VAT not included
|
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Trillium Therapeutics Inc | TRIL | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Low Price | High Price | Open Price | Close Price | Last Traded  |
|
|---|---|---|---|---|---|---|---|---|
| 0.02 | 0.48% | 4.18 | 3.92 | 4.45 | 4.18 | 4.16 | 19:06:45 |
| Bid Price | Ask Price | Spread | Spread % | News | |
|---|---|---|---|---|---|
| 4.18 | 4.20 | 0.02 | 0.48% | - | - |
| Stock Trades | Traded Volume | VWAP | Dollar Volume | Average Volume | 52 Week Range |
|---|---|---|---|---|---|
| 8,710 | 3,130,364 | $ 4.25 | $ 13,306,085 | 6,339,623 | 0.2405 - 4.90 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 19:59:26 | 2 | $ 4.18 | USD |
Trillium Therapeutics Financials
| Market Cap | Shares in Issue | Profit/Loss | Earnings Per Share (EPS) | PE Ratio | Float |
|---|---|---|---|---|---|
| $ 313.37M | 74.97M | $ -42.49M | - | - | 69.32M |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | $ - | 0.00% | - | - |
Trillium Therapeutics News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical TRIL Price Data
| Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 3.65 | 4.45 | 3.352 | 3.89 | 1,804,668 | 0.53 | 14.52% |
| 1 Month | 4.14 | 4.90 | 3.352 | 4.14 | 2,282,675 | 0.04 | 0.97% |
| 3 Months | 0.339 | 4.90 | 0.2801 | 2.61 | 4,527,411 | 3.84 | 1,133.04% |
| 6 Months | 0.2829 | 4.90 | 0.2405 | 2.47 | 2,162,816 | 3.90 | 1,377.55% |
| 1 Year | 1.22 | 4.90 | 0.2405 | 1.97 | 1,484,264 | 2.96 | 242.62% |
| 3 Years | 6.70 | 13.30 | 0.2405 | 2.38 | 565,649 | -2.52 | -37.61% |
| 5 Years | 13.60 | 29.92 | 0.2405 | 3.76 | 385,762 | -9.42 | -69.26% |
Trillium Therapeutics Description
| Trillium Therapeutics Inc is a Canadian clinical stage immuno-oncology company which is engaged in developing therapies for the treatment of cancer. The lead program of the company is TTI-621 which is designed to act as a soluble decoy receptor, preventing CD47 from delivering its inhibitory signal. The company has proprietary medicinal chemistry platform, using fluorine chemistry which permits the creation of new chemical entities with pharmacological properties. The company operates through the single segment being Research and development of therapies for the treatment of cancer. |
